197 related articles for article (PubMed ID: 22733075)
1. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.
Butler MM; Shinabarger DL; Citron DM; Kelly CP; Dvoskin S; Wright GE; Feng H; Tzipori S; Bowlin TL
Antimicrob Agents Chemother; 2012 Sep; 56(9):4786-92. PubMed ID: 22733075
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
6. A novel agent effective against Clostridium difficile infection.
Dvoskin S; Xu WC; Brown NC; Yanachkov IB; Yanachkova M; Wright GE
Antimicrob Agents Chemother; 2012 Mar; 56(3):1624-6. PubMed ID: 22203600
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone resistance and Clostridium difficile, Germany.
Zaiss NH; Witte W; Nübel U
Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
[TBL] [Abstract][Full Text] [Related]
8. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of nitazoxanide against Clostridium difficile.
McVay CS; Rolfe RD
Antimicrob Agents Chemother; 2000 Sep; 44(9):2254-8. PubMed ID: 10952564
[TBL] [Abstract][Full Text] [Related]
12. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C
Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
[TBL] [Abstract][Full Text] [Related]
14. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
[TBL] [Abstract][Full Text] [Related]
15. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
[TBL] [Abstract][Full Text] [Related]
16. Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile.
Duvall JR; Bedard L; Naylor-Olsen AM; Manson AL; Bittker JA; Sun W; Fitzgerald ME; He Z; Lee MD; Marie JC; Muncipinto G; Rush D; Xu D; Xu H; Zhang M; Earl AM; Palmer MA; Foley MA; Vacca JP; Scherer CA
ACS Infect Dis; 2017 May; 3(5):349-359. PubMed ID: 28215073
[TBL] [Abstract][Full Text] [Related]
17. A high-throughput small-molecule screen to identify a novel chemical inhibitor of Clostridium difficile.
Katzianer DS; Yano T; Rubin H; Zhu J
Int J Antimicrob Agents; 2014 Jul; 44(1):69-73. PubMed ID: 24837414
[TBL] [Abstract][Full Text] [Related]
18. Repurposing the Veterinary Antiprotozoal Drug Ronidazole for the Treatment of Clostridioides difficile Infection.
AbdelKhalek A; Seleem MN
Int J Antimicrob Agents; 2020 Dec; 56(6):106188. PubMed ID: 33045352
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution.
Wolfe C; Pagano P; Pillar CM; Shinabarger DL; Boulos RA
Diagn Microbiol Infect Dis; 2018 Nov; 92(3):250-252. PubMed ID: 30042035
[TBL] [Abstract][Full Text] [Related]
20. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]